<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206630">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398567</url>
  </required_header>
  <id_info>
    <org_study_id>3144A1-202</org_study_id>
    <secondary_id>B1891013</secondary_id>
    <nct_id>NCT00398567</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer</brief_title>
  <official_title>A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puma Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puma Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether it is safe and effective to administer HKI-272
      (neratinib) in combination with Herceptin in patients with advanced breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label phase 1/2 study of ascending multiple oral doses of HKI-272 in combination with
      IV Herceptin in subjects with advanced HER2+ breast cancer. Three to six subjects will be
      enrolled in each dose group. Adverse events and dose limiting toxicities will be assessed
      from the first dose of study drug though day 21. When the maximum tolerated dose of HKI-272
      plus Herceptin is determined, an additional 30 subjects will be enrolled at that dose level,
      and followed for progression free survival for approximately 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>At screening, weekly for the first month, then at weeks 1 and 4 thereafter, and at the final visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>At screening and then every 2 months throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed maximum concentration of HKI-272 (neratinib)</measure>
    <time_frame>Prior to the first dose, on days 22 through 23 of month 1, and on day 1 in months 2 through 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration of HKI-272 (neratinib)</measure>
    <time_frame>Prior to the first dose, on days 22 through 23 of month 1, and on day 1 in months 2 through 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve of HKI-272 (neratinib)</measure>
    <time_frame>Prior to the first dose, on days 22 through 23 of month 1, and on day 1 in months 2 through 6</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 - dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - expanded MTD cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HKI-272</intervention_name>
    <description>neratinib 160 mg daily by mouth</description>
    <arm_group_label>Part 1 - dose level 1</arm_group_label>
    <other_name>neratinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter</description>
    <arm_group_label>Part 1 - dose level 1</arm_group_label>
    <other_name>trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HKI-272</intervention_name>
    <description>neratinib 160 mg daily by mouth</description>
    <arm_group_label>Part 1 - dose level 2</arm_group_label>
    <other_name>neratinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter</description>
    <arm_group_label>Part 1 - dose level 2</arm_group_label>
    <other_name>trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HKI-272</intervention_name>
    <description>neratinib 240 mg daily by mouth</description>
    <arm_group_label>Part 2 - expanded MTD cohort</arm_group_label>
    <other_name>neratinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter</description>
    <arm_group_label>Part 2 - expanded MTD cohort</arm_group_label>
    <other_name>trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic diagnosis of breast cancer with current stage IIIB, IIIC or IV not curable
             by available therapy

          -  Progression following at least one Herceptin-containing cytotoxic chemotherapy
             regimen (neoadjuvant, adjuvant, or metastatic setting)

          -  HER2 positive breast cancer

          -  At least one measurable target lesion

          -  Adequate performance status

          -  Adequate cardiac, kidney, and liver function

          -  Adequate blood counts

          -  Willingness of all subjects who are not surgically sterile or post menopausal to use
             acceptable methods of birth control

        Exclusion Criteria:

          -  More than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic
             disease

          -  Major surgery, chemotherapy, radiotherapy, investigational agents, Herceptin or other
             cancer therapy within 2 weeks of treatment day 1

          -  Prior treatment with anthracyclines with cumulative dose of &gt;400 mg/m^2

          -  Extensive visceral disease

          -  Active central nervous system metastases

          -  Pregnant or breast feeding women

          -  Significant chronic or recent acute gastrointestinal disorder with diarrhea as a
             major symptom

          -  Prior exposure to HKI-272 or other HER2 targeted agents (except Herceptin and Tykerb)

          -  Significant cardiac disease or dysfunction

          -  History of life-threatening hypersensitivity to Herceptin

          -  Inability or unwillingness to swallow HKI-272 capsules

          -  Any other cancer within 5 years with the exception of contralateral breast cancer,
             adequately treated cervical carcinoma in situ, or adequately treated basal or
             squamous cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Puma</last_name>
    <role>Study Director</role>
    <affiliation>Biotechnology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>France</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 30, 2016</lastchanged_date>
  <firstreceived_date>November 9, 2006</firstreceived_date>
  <firstreceived_results_disposition_date>February 25, 2011</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HKI-272</keyword>
  <keyword>neratinib</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>Herceptin</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
